Hong JH[au] - Search Results

Year	Number of Results
1974	2
1976	1
1977	1
1979	2
1980	1
1981	3
1987	5
1988	1
1989	7
1990	11
1991	15
1992	15
1993	18
1994	7
1995	8
1996	13
1997	9
1998	11
1999	13
2000	19
2001	15
2002	14
2003	17
2004	26
2005	32
2006	47
2007	39
2008	63
2009	66
2010	78
2011	95
2012	92
2013	99
2014	111
2015	134
2016	110
2017	131
2018	116
2019	128
2020	149
2021	146
2022	55

1

A Comprehensive Review on Current Advances in Peptide Drug Development and Design.

Lee AC, Harris JL, Khanna KK, Hong JH. Lee AC, et al. Among authors: hong jh. Int J Mol Sci. 2019 May 14;20(10):2383. doi: 10.3390/ijms20102383. Int J Mol Sci. 2019. PMID: 31091705 Free PMC article. Review.

2

Reply by Authors.

Pak S, Park SY, Shin TJ, You D, Jeong IG, Hong JH, Kim CS, Ahn H. Pak S, et al. Among authors: hong jh. J Urol. 2019 Sep;202(3):531-532. doi: 10.1097/01.JU.0000569236.63335.db. Epub 2019 Aug 8. J Urol. 2019. PMID: 31192753 No abstract available.

3

Emphysematous osteomyelitis of spine.

Ko IK, Hong JH. Ko IK, et al. Among authors: hong jh. Br J Neurosurg. 2019 Oct 18:1-2. doi: 10.1080/02688697.2019.1678739. Online ahead of print. Br J Neurosurg. 2019. PMID: 31625398 No abstract available.

4

Physiological application of nanoparticles in calcium-related proteins and channels.

Lee D, Hong JH. Lee D, et al. Among authors: hong jh. Nanomedicine (Lond). 2019 Sep;14(18):2479-2486. doi: 10.2217/nnm-2019-0004. Epub 2019 Aug 28. Nanomedicine (Lond). 2019. PMID: 31456482 Review.

5

Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.

Hong JH, Kwon YS, Kim IY. Hong JH, et al. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):183-192. doi: 10.1080/17425255.2017.1244265. Epub 2016 Oct 21. Expert Opin Drug Metab Toxicol. 2017. PMID: 27690667 Review.

6

Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer.

Hong JH. Hong JH. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):361-369. doi: 10.1080/17425255.2018.1440288. Epub 2018 Feb 13. Expert Opin Drug Metab Toxicol. 2018. PMID: 29431540 Review.

7

Paradigm shift in the management of type B insulin resistance.

Hong JH, Kim HJ, Park KS, Ku BJ. Hong JH, et al. Ann Transl Med. 2018 Dec;6(Suppl 2):S98. doi: 10.21037/atm.2018.11.21. Ann Transl Med. 2018. PMID: 30740419 Free PMC article. No abstract available.

8

Recent advances in the synthesis of cyclic 5'-nornucleoside phosphonate analogues.

Shen GH, Hong JH. Shen GH, et al. Among authors: hong jh. Carbohydr Res. 2018 Jun 30;463:47-106. doi: 10.1016/j.carres.2018.04.009. Epub 2018 Apr 28. Carbohydr Res. 2018. PMID: 29772449 Review.

9

An MG53-IRS1-interaction disruptor ameliorates insulin resistance.

Park JS, Lee H, Choi BW, Ro S, Lee D, Na JE, Hong JH, Lee JS, Kim BW, Ko YG. Park JS, et al. Among authors: hong jh. Exp Mol Med. 2018 Jun 6;50(6):1-12. doi: 10.1038/s12276-018-0099-9. Exp Mol Med. 2018. PMID: 29884820 Free PMC article.

10

Carbon nanotubes as cancer therapeutic carriers and mediators.

Son KH, Hong JH, Lee JW. Son KH, et al. Among authors: hong jh. Int J Nanomedicine. 2016 Oct 7;11:5163-5185. doi: 10.2147/IJN.S112660. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27785021 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results